MSN Labs inks pact with Eli Lilly on covid drug baricitinib

Our Bureau | | Updated on: Jul 02, 2021

FILE PHOTO: FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File Photo/File Photo | Photo Credit: Mike Segar

Will be launched under the brand name BARIDOZ in two strengths-2 mg and 4mg


MSN Labs has entered into a royalty-free, non-exclusive, voluntary license agreement with the US-based Eli Lilly and Co for manufacturing and marketing of baricitinib in India.

The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization for emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

“This collaboration with Eli Lilly and Co is a landmark milestone in India’s fight against Covid-19 and will thus help in increasing the availability and affordability of baricitinib,'' MSN Reddy, CMD – MSN Group said in a release on Thursday.

Hyderabad-based MSN will be launching the product under the brand name BARIDOZ in two strengths-2 mg and 4mg. MSN has developed the active pharmaceutical ingredient and the formulation of baricitinib in its in-house R&D and manufacturing units.

As part of the Covid treatment range, MSN has already launched Favilow (Favipiravir) and Oselow (Oseltamivir).

Published on May 13, 2021
This article is closed for comments.
Please Email the Editor

You May Also Like

Recommended for you